# STFS (Star Fashion Culture Holdings Limited) - SEC EDGAR Financial Statements

> Star Fashion Culture Holdings Limited reported ¥210.2M in revenue and a net loss of ¥28.75M for the fiscal year ended June 30, 2026 (up 74.0% year over year), with a 7.7% gross margin and a -16.2% operating margin.

- Canonical: https://convexityos.com/fundamentals/STFS
- Markdown: https://convexityos.com/fundamentals/STFS.md
- SEC CIK: 0002003061
- Reporting currency: CNY
- Latest filing period: June 30, 2026
- Last synced: Nov 20, 2026, 05:51 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002003061&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | ¥210.2M | +74.0% YoY |
| Operating Income | FY 2026 | -¥34.12M | -16.2% margin |
| Net Income | FY 2026 | -¥28.75M | -13.7% net margin |
| Diluted EPS | FY 2026 | -¥28.76 | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | ¥471K | Total debt: ¥3.76M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| **Revenue** | ¥210.2M | ¥120.8M | ¥108.8M | ¥69.04M |
| Cost of Revenue | ¥194.1M | ¥113.9M | ¥91.81M | ¥49.53M |
| **Gross Profit** | ¥16.11M | ¥6.86M | ¥16.99M | ¥19.51M |
| Selling, General & Admin | ¥50.23M | ¥136.6M | ¥2.94M | ¥8.86M |
| Total Operating Expenses | ¥50.23M | ¥136.6M | ¥2.94M | ¥8.86M |
| **Operating Income** | -¥34.12M | -¥129.7M | ¥14.06M | ¥10.66M |
| Interest Expense | ¥164K | ¥206K | ¥199K | ¥448K |
| Income Before Tax | -¥28.47M | -¥129.6M | ¥14.95M | ¥10.44M |
| Income Tax Expense | ¥273K | ¥1.22M | ¥3.74M | ¥2.62M |
| **Net Income** | -¥28.75M | -¥130.8M | ¥11.21M | ¥7.82M |
| Basic EPS | -¥28.76 | -¥375.14 | ¥44.84 | ¥893.98 |
| **Diluted EPS** | -¥28.76 | -¥375.14 | ¥44.84 | ¥893.98 |
| Basic Shares Outstanding | 999.3K | 348.8K | 250.0K | 8.7K |
| Diluted Shares Outstanding | 999.3K | 348.8K | 250.0K | 8.7K |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | ¥471K | ¥469K | ¥1.25M |
| **Cash & Short-Term Investments** | ¥471K | ¥469K | ¥1.25M |
| Accounts Receivable, Net | ¥61.18M | ¥43.78M | ¥41.47M |
| **Total Current Assets** | ¥109.3M | ¥87.34M | ¥58.66M |
| Intangible Assets | ¥24.68M | -- | -- |
| **Total Non-Current Assets** | ¥24.68M | ¥0 | ¥1.22M |
| **Total Assets** | ¥134.0M | ¥87.34M | ¥59.88M |
| Accounts Payable | ¥12.96M | ¥17.15M | ¥18.15M |
| Short-Term Debt | ¥3.76M | ¥4.28M | ¥4.70M |
| Deferred Revenue (Current) | ¥3.47M | ¥2.38M | ¥2.12M |
| **Total Current Liabilities** | ¥33.26M | ¥41.42M | ¥37.45M |
| **Total Non-Current Liabilities** | ¥0 | ¥0 | ¥0 |
| **Total Liabilities** | ¥33.26M | ¥41.42M | ¥37.45M |
| **Total Debt (incl. Leases)** | ¥3.76M | ¥4.28M | ¥4.70M |
| Retained Earnings | -¥168.6M | -¥139.9M | -¥9.07M |
| **Total Stockholders' Equity** | ¥100.7M | ¥45.92M | ¥22.43M |
| Total Equity | ¥100.7M | ¥45.92M | ¥22.43M |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Jun 2025 | Jun 2024 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | ¥471K | ¥469K | ¥1.25M |
| **Cash & Short-Term Investments** | ¥471K | ¥469K | ¥1.25M |
| Accounts Receivable, Net | ¥61.18M | ¥43.78M | ¥41.47M |
| **Total Current Assets** | ¥109.3M | ¥87.34M | ¥58.66M |
| Intangible Assets | ¥24.68M | -- | -- |
| **Total Non-Current Assets** | ¥24.68M | ¥0 | ¥1.22M |
| **Total Assets** | ¥134.0M | ¥87.34M | ¥59.88M |
| Accounts Payable | ¥12.96M | ¥17.15M | ¥18.15M |
| Short-Term Debt | ¥3.76M | ¥4.28M | ¥4.70M |
| Deferred Revenue (Current) | ¥3.47M | ¥2.38M | ¥2.12M |
| **Total Current Liabilities** | ¥33.26M | ¥41.42M | ¥37.45M |
| **Total Non-Current Liabilities** | ¥0 | ¥0 | ¥0 |
| **Total Liabilities** | ¥33.26M | ¥41.42M | ¥37.45M |
| **Total Debt (incl. Leases)** | ¥3.76M | ¥4.28M | ¥4.70M |
| Retained Earnings | -¥168.6M | -¥139.9M | -¥9.07M |
| **Total Stockholders' Equity** | ¥100.7M | ¥45.92M | ¥22.43M |
| Total Equity | ¥100.7M | ¥45.92M | ¥22.43M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| Net Income | -¥28.75M | -¥130.8M | ¥11.21M | ¥7.82M |
| Stock-Based Compensation | ¥20.57M | ¥119.6M | -- | -- |
| Change in Receivables | -¥25.36M | -¥11.44M | -¥26.01M | -¥9.14M |
| Change in Payables | -¥4.18M | -¥1.01M | ¥978K | ¥2.83M |
| **Operating Cash Flow** | -¥26.75M | -¥28.40M | ¥7.23M | -¥29.61M |
| **Investing Cash Flow** | -¥35.69M | -¥14.35M | -- | -- |
| **Financing Cash Flow** | ¥62.44M | ¥41.97M | -¥6.03M | ¥29.62M |
| **Net Change in Cash** | ¥2.5K | -¥784K | ¥1.20M | ¥8.6K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- | --- |
| **Gross Margin** | 7.7% | 5.7% | 15.6% | 28.3% |
| **Operating Margin** | -16.2% | -107.4% | 12.9% | 15.4% |
| **Net Profit Margin** | -13.7% | -108.3% | 10.3% | 11.3% |
| Return on Equity (ROE) | -28.5% | -284.9% | 50.0% | -- |
| Return on Assets (ROA) | -21.5% | -149.8% | 18.7% | -- |
| Current Ratio | 3.29x | 2.11x | 1.57x | -- |
| Quick Ratio | 1.85x | 1.07x | 1.14x | -- |
| Debt to Equity | 0.04x | 0.09x | 0.21x | -- |
| **Revenue Growth (YoY)** | +74.0% | +11.0% | +57.6% | -- |
| Gross Profit Growth (YoY) | +134.8% | -59.6% | -12.9% | -- |
| Operating Income Growth (YoY) | -- | -1022.8% | +31.9% | -- |
| **Net Income Growth (YoY)** | -- | -1267.1% | +43.4% | -- |
| EPS Growth (YoY) | -- | -936.6% | -95.0% | -- |
| Operating Cash Flow Growth (YoY) | -- | -492.6% | -- | -- |

## Related Companies

[AIFC (AI Financial Corporation)](https://convexityos.com/fundamentals/AIFC), [HIT (Health In Tech, Inc.)](https://convexityos.com/fundamentals/HIT), [BNGO (Bionano Genomics, Inc.)](https://convexityos.com/fundamentals/BNGO), [VSTM (Verastem, Inc.)](https://convexityos.com/fundamentals/VSTM), [LIFD (Lftd Partners Inc.)](https://convexityos.com/fundamentals/LIFD), [DRCT (Direct Digital Holdings, Inc.)](https://convexityos.com/fundamentals/DRCT), [INFQ (Infleqtion, Inc.)](https://convexityos.com/fundamentals/INFQ), [AMS (American Shared Hospital Services)](https://convexityos.com/fundamentals/AMS)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
